Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 7
1997 8
1998 3
1999 12
2000 12
2001 15
2002 19
2003 36
2004 32
2005 48
2006 40
2007 71
2008 36
2009 32
2010 35
2011 39
2012 27
2013 32
2014 34
2015 11
2016 24
2017 21
2018 15
2019 14
2020 16
2021 14
2022 12
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

597 results
Results by year
Filters applied: . Clear all
Page 1
Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine.
Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Hershey AD; CHAMP Investigators. Powers SW, et al. N Engl J Med. 2017 Jan 12;376(2):115-124. doi: 10.1056/NEJMoa1610384. Epub 2016 Oct 27. N Engl J Med. 2017. PMID: 27788026 Free PMC article. Clinical Trial.
There were no significant between-group differences in the primary outcome, which occurred in 52% of the patients in the amitriptyline group, 55% of those in the topiramate group, and 61% of those in the placebo group (amitriptyline vs. placebo, P=0.26; topiramate v …
There were no significant between-group differences in the primary outcome, which occurred in 52% of the patients in the amitriptyline group …
Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.
Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, Hours-Zesiger P, Nickisch J, Sieder C, Hentschke C, Maier-Peuschel M. Reuter U, et al. Cephalalgia. 2022 Feb;42(2):108-118. doi: 10.1177/03331024211053571. Epub 2021 Nov 7. Cephalalgia. 2022. PMID: 34743579 Free PMC article. Clinical Trial.
Patients with 4 migraine days per month and naive to study drugs were randomly assigned (1:1) to either subcutaneous erenumab (70 or 140 mg/month) plus topiramate placebo (erenumab group) or oral topiramate at the individual dose with optimal efficacy (50-100 mg/day …
Patients with 4 migraine days per month and naive to study drugs were randomly assigned (1:1) to either subcutaneous erenumab (70 or 140 mg/ …
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D. Elkind-Hirsch KE, et al. J Clin Endocrinol Metab. 2021 Sep 27;106(10):3019-3033. doi: 10.1210/clinem/dgab408. J Clin Endocrinol Metab. 2021. PMID: 34097062 Clinical Trial.
OBJECTIVE: The efficacy of once-weekly exenatide (EQW) and dapagliflozin (DAPA) alone and coadministered (EQW/DAPA), DAPA/extended-release (ER) metformin (DAPA/MET), and phentermine topiramate extended release (PHEN/TPM) on metabolic parameters, body composition, and sex h …
OBJECTIVE: The efficacy of once-weekly exenatide (EQW) and dapagliflozin (DAPA) alone and coadministered (EQW/DAPA), DAPA/extended-release ( …
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR; SANAD Study group. Marson AG, et al. Lancet. 2007 Mar 24;369(9566):1016-26. doi: 10.1016/S0140-6736(07)60461-9. Lancet. 2007. PMID: 17382828 Free PMC article. Clinical Trial.
Patients were randomly assigned to valproate, lamotrigine, or topiramate between Jan 12, 1999, and Aug 31, 2004, and follow-up data were obtained up to Jan 13, 2006. ...But there was no significant difference between valproate and topiramate in either the analysis o …
Patients were randomly assigned to valproate, lamotrigine, or topiramate between Jan 12, 1999, and Aug 31, 2004, and follow-up data w …
Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. Allison DB, et al. Obesity (Silver Spring). 2012 Feb;20(2):330-42. doi: 10.1038/oby.2011.330. Epub 2011 Nov 3. Obesity (Silver Spring). 2012. PMID: 22051941 Free PMC article. Clinical Trial.
A 56-week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled-release combination of phentermine and topiramate (PHEN/TPM CR) for weight loss (WL) and metabolic improvements. ...
A 56-week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled-release combination of phentermine and …
FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
Rothrock JF, Adams AM, Lipton RB, Silberstein SD, Jo E, Zhao X, Blumenfeld AM; FORWARD Study investigative group. Rothrock JF, et al. Headache. 2019 Nov;59(10):1700-1713. doi: 10.1111/head.13653. Epub 2019 Sep 26. Headache. 2019. PMID: 31559634 Free PMC article. Clinical Trial.
RESULTS: We enrolled 282 patients (onabotulinumtoxinA, n = 140; topiramate, n = 142) and 148 patients completed randomized treatment (onabotulinumtoxinA, n = 120 [86%]; topiramate, n = 28 [20%]). Primary reasons for withdrawal were ineffective treatment (onabotulinu …
RESULTS: We enrolled 282 patients (onabotulinumtoxinA, n = 140; topiramate, n = 142) and 148 patients completed randomized treatment …
A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa.
Safer DL, Adler S, Dalai SS, Bentley JP, Toyama H, Pajarito S, Najarian T. Safer DL, et al. Int J Eat Disord. 2020 Feb;53(2):266-277. doi: 10.1002/eat.23192. Epub 2019 Nov 13. Int J Eat Disord. 2020. PMID: 31721257 Clinical Trial.
OBJECTIVE: Open trials suggest phentermine/topiramate ER (PHEN/TPM-ER), food and drug administration (FDA) approved for obesity, has utility for binge eating. ...
OBJECTIVE: Open trials suggest phentermine/topiramate ER (PHEN/TPM-ER), food and drug administration (FDA) approved for obesity, has …
Effects of topiramate on the association between affect, cannabis craving, and cannabis use in the daily life of youth during a randomized clinical trial.
Emery NN, Carpenter RW, Meisel SN, Miranda R Jr. Emery NN, et al. Psychopharmacology (Berl). 2021 Nov;238(11):3095-3106. doi: 10.1007/s00213-021-05925-5. Epub 2021 Jul 31. Psychopharmacology (Berl). 2021. PMID: 34331080 Free PMC article. Clinical Trial.
RATIONALE: Topiramate is an anticonvulsant currently under study for treating substance use disorders. ...Importantly, topiramate also impacts mood states central to many models of substance use. ...
RATIONALE: Topiramate is an anticonvulsant currently under study for treating substance use disorders. ...Importantly, topiramate …
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Gadde KM, et al. Lancet. 2011 Apr 16;377(9774):1341-52. doi: 10.1016/S0140-6736(11)60205-5. Epub 2011 Apr 8. Lancet. 2011. PMID: 21481449 Clinical Trial.
FINDINGS: Of 2487 patients, 994 were assigned to placebo, 498 to phentermine 7.5 mg plus topiramate 46.0 mg, and 995 to phentermine 15.0 mg plus topiramate 92.0 mg; 979, 488, and 981 patients, respectively, were analysed. At 56 weeks, change in bodyweight was -1.4 k …
FINDINGS: Of 2487 patients, 994 were assigned to placebo, 498 to phentermine 7.5 mg plus topiramate 46.0 mg, and 995 to phentermine 1 …
Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users.
Levin FR, Mariani JJ, Pavlicova M, Choi CJ, Mahony AL, Brooks DJ, Bisaga A, Dakwar E, Carpenter KM, Naqvi N, Nunes EV, Kampman K. Levin FR, et al. Drug Alcohol Depend. 2020 Jan 1;206:107700. doi: 10.1016/j.drugalcdep.2019.107700. Epub 2019 Nov 1. Drug Alcohol Depend. 2020. PMID: 31753736 Free PMC article. Clinical Trial.
BACKGROUND: Cocaine use disorder (CUD) remains a substantial public health problem with no clearly effective pharmacotherapy available. In a prior trial, combined amphetamine and topiramate treatment significantly reduced cocaine use among individuals demonstrating the mos …
BACKGROUND: Cocaine use disorder (CUD) remains a substantial public health problem with no clearly effective pharmacotherapy available. In a …
597 results